LexaGene Holdings, Inc., (OTCQB: LXXGF) (TSX-V: LXG) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce that it has initiated a program that uses the rapid configurability of the MiQLab™ system to investigate novel variants of SARS-CoV-2, the pathogen that causes COVID-19. SARS-CoV-2 is a pathogen that. LexaGene Holdings, Inc., (OTCQB: LXXGF) (TSX-V: LXG) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce that it has initiated a program that uses the rapid configurability of the MiQLab™ system to investigate novel variants of SARS-CoV-2, the pathogen that causes COVID-19.
NZRPA Mitre 10 Cup Young Player of the Year Freedom Vahaakolo in action for Otago against Tasman.
Outstanding Otago wing Freedom Vahaakolo has been snapped up by the Highlanders on a short-term contract. Vahaakolo scored seven tries in his debut season for Otago last year and won the NZRPA Mitre 10 Young Player of the Year award, impressing his peers with his pace, power and finishing ability.
Joe Allison/Getty Images
Highlanders fans were puzzled when Freedom Vahaakolo missed out on a Super Rugby contract. Eyebrows were therefore raised when he missed out on a full Super Rugby contract but the door has now opened in Dunedin, with Highlanders wing Sam Gilbert not expected to be available until April as he recovers from the ACL injury he suffered last year.
Image by Pete Linforth from Pixabay
Dr. Jack Regan, LexaGene’s CEO and Founder states, “I’m excited we have progressed to the point where we have started our FDA study. Our open-access technology is unlike any other on the market today, as it could be configured quickly to detect new variants, such as the recent UK variant (aka SARS-CoV-2 VUI 202012/01). Since our system is capable of high multiplexing and is microfluidic in nature, it is easy to add newly developed Polymerase Chain Reaction (PCR) tests to detect variants that are either poor matches to the vaccines or are resistant to any developed therapies, which is critical to help get this pandemic under control.”
[December 30, 2020]
LexaGene Starts FDA EUA Study for Point-of-Care COVID-19 Testing
Companyâ), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce that it has started a series of studies required by the FDA for Emergency Use Authorization (EUA) testing for its COVID-19 assay in a point-of-care (POC) environment using its fully automated MiQLab⢠system.
Dr. Jack Regan, LexaGeneâs CEO and Founder states, âIâm excited we have progressed to the point where we have started our FDA study. Our open-access technology is unlike any other on the market today, as it could be configured quickly to detect new variants, such as the recent UK variant
Erster Weltkrieg: Weihnachtsfrieden 1914 - Als Deutsche und Briten gemeinsam feiern mdr.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mdr.de Daily Mail and Mail on Sunday newspapers.